跳转至内容
Merck
CN

L3791

拉莫三嗪

≥98% (TLC), powder, glutamate release inhibitor

别名:

6-（2,3-二氯苯基）-1,2,4-三嗪-3,5-二胺, GI 267119X

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C9H7Cl2N5
化学文摘社编号:
84057-84-1
分子量:
256.09
NACRES:
NA.77
PubChem Substance ID:
24278792
UNSPSC Code:
12352200
EC Number:
281-901-8
MDL number:
MFCD00865333

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

拉莫三嗪, ≥98%, powder

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

InChI key

PYZRQGJRPPTADH-UHFFFAOYSA-N

SMILES string

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

assay

≥98%

form

powder

color

white

solubility

DMSO: soluble 20 mg/mL at 60 °C
H2O: insoluble

originator

GlaxoSmithKline

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scn2a1(24766), Scnn1a(25122)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

抗惊厥药。

Features and Benefits

该化合物由 GlaxoSmithKline 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单，请单击此处。

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
MKCZ2217
MKCZ1543
MKCW2040
MKCH9792
MKCF2209

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Crystal T Clark et al.
The American journal of psychiatry, 170(11), 1240-1247 (2013-11-05)
Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder. The authors present new data on serial serum levels of lamotrigine in pregnant patients on lamotrigine monotherapy. They also review the epilepsy
Stacey Shim et al.
The Journal of pharmacology and experimental therapeutics, 347(2), 487-496 (2013-08-30)
Carisbamate and lamotrigine are anticonvulsants that act on neuronal voltage-gated sodium channels. Carisbamate has shown antidepressant-like effects in animal models of depression, and lamotrigine is a mood stabilizer with a therapeutic effect in depressive episodes of patients with bipolar disorder.
Chaitali Ghosh et al.
Epilepsia, 54(9), 1562-1570 (2013-07-20)
Brain drug bioavailability is regulated by the blood-brain barrier (BBB). It was recently suggested that cytochrome P450 (CYP) enzymes could act in concert with multidrug transporter proteins to regulate drug penetration and distribution into the diseased brain. The possibility that
Allyson K Friedman et al.
Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)
Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA
Kerstin Römermann et al.
Neuropharmacology, 93, 7-14 (2015-02-04)
Resistance to antiepileptic drugs (AEDs) is the major problem in the treatment of epilepsy. One hypothesis to explain AED resistance suggests that seizure-induced overexpression of efflux transporters at the blood-brain barrier (BBB) restricts AEDs to reach their brain targets. Various
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持